We are excited to announce that the first patient has been dosed in a Phase I Trial with SNV4818, a potential best-in-class pan-mutant-selective PI3Kα inhibitor for the treatment of solid tumors.?This marks the second Synnovation program to enter the clinic in just three years since our formation. https://lnkd.in/g6C3HJR9
Synnovation Therapeutics
制药业
Wilmington，DE 3,228 位关注者
A precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers
关于我们
Synnovation Therapeutics is a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets. We are dedicated to the discovery and development of best-in-class therapeutics that can improve the lives of people living with cancer. Leveraging deep expertise in cancer biology and a world class medicinal chemistry team, we are building a diverse pipeline of novel small molecule targeted therapies. Our mission is to efficiently advance these agents into clinical trials with the goal of transforming cancer care through patient-focused precision medicine.
- 网站
-
https://www.synnovationtx.com
Synnovation Therapeutics的外部链接
- 所属行业
- 制药业
- 规模
- 11-50 人
- 总部
- Wilmington，DE
- 类型
- 私人持股
- 创立
- 2021
- 领域
- Medicinal Chemistry、Cellular Assays、In Vivo Pharmocology、Process Chemistry、Drug Discovery和Biochemical Assays
地点
-
主要
获取路线
200 Powder Mill Road
US，DE，Wilmington，19803
Synnovation Therapeutics员工
动态
-
We're #hiring a new Director of Immunology in Wilmington, Delaware. Apply today or share this post with your network.
-
We're #hiring a new Senior Research Investigator - Medicinal Chemistry in Wilmington, Delaware. Apply today or share this post with your network.
-
Synnovation is excited to announce that David Butera has joined as Senior Vice President, Business Development. Dave is a seasoned and widely respected leader who brings over twenty years of combined business development, consulting, venture capital and research experience. Dave’s broad expertise in all facets of business and corporate development will be instrumental to Synnovation’s mission to discover and develop best-in-class therapeutics that improve the lives of patients.?Most recently, Dave served as Executive Director, Business Development at Incyte. Prior to Incyte, Dave worked in management consulting and venture capital, and spent his early career conducting cancer and infectious disease research at Massachusetts General Hospital and the Rockefeller University.??
-
We're #hiring a new Senior Research Investigator to Associate Director, Cancer Biology in Wilmington, Delaware. Apply today or share this post with your network.
-
Synnovation Therapeutics will be presenting 2 posters at the 2024 AACR annual meeting next week. The abstracts accepted for presentation are: Title: Discovery of a novel and potent mutant-selective inhibitor of PI3Kα Abstract No.: 1956 Presenter: Mingming Gao, Ph.D. Senior Director, Biology Date/Time: Monday, April 8, 2024, 9:00 AM - 12:30 PM Session: Kinase and Phosphatase Inhibitors -2 Title: Activity of PARP1-selective inhibitor SNV-001 in models of HRD cancers as monotherapy and in combination Abstract No.: 4562 Presenter: Zhentian Li, Ph.D. Principal Investigator, Biology Date/Time: Tuesday, April 9, 2024, 9:00 AM - 12:30 PM Session: Drug Combinations We look forward to seeing you in San Diego!
-
We're #hiring a new Sr. Research Investigator - Medicinal Chemistry in Wilmington, Delaware. Apply today or share this post with your network.